Multiple Primary Melanomas and Metastatic Neuroendocrine Tumor in a <scp>POT1</scp> Pathogenic Variant Carrier

Dr. Di Meo received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Almirall, Sunpharma, MSD, Sanofi, and Pfizer. Dr. Zalaudek received data safety monitoring board support from Philogen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Sanofi Genzyme, Sunpharma, Novartis, MSD, BMS, Philogen, Biogena, La Roche Posay, Kyowara Kirin, Fotofinder, Mallinckrodt, Cieffe Derma, Pierre Fabre, Regeneron, Canova, Almirall, and Beiersdorf; and support for attending meetings and/or travel from Difa Cooper. The other authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.